Literature DB >> 25422846

Endothelial permeability and VE-cadherin: a wacky comradeship.

Julie Gavard.   

Abstract

The endothelium forms a selective semi-permeable barrier controlling bidirectional transfer between blood vessel and irrigated tissues. This crucial function relies on the dynamic architecture of endothelial cell–cell junctions, and in particular, VE -cadherin-mediated contacts. VE -cadherin indeed chiefly organizes the opening and closing of the endothelial barrier, and is central in permeability changes. In this review, the way VE -cadherin-based contacts are formed and maintained is first presented, including molecular traits of its expression, partners, and signaling. In a second part, the mechanisms by which VE -cadherin adhesion can be disrupted, leading to cell–cell junction weakening and endothelial permeability increase, are described. Overall, the molecular basis for VE -cadherin control of the endothelial barrier function is of high interest for biomedical research, as vascular leakage is observed in many pathological conditions and human diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25422846      PMCID: PMC4049861          DOI: 10.4161/cam.29026

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


Cell–cell interactions are dynamic structures allowing cohesion and plasticity of organs. In vascular endothelial cells, endothelial junctions have to maintain homeostasis of blood vessels, while they retain their ability to rearrange during angiogenesis. Both adherens (AJs) and tight junctions (TJs) join neighboring cells together, and can adapt quickly to changes in the perivascular microenvironment, such as angiogenic/antiangiogenic cues, blood flow, shear stress, inflammatory conditions, etc. The AJ protein, VE-cadherin (vascular endothelial cadherin, also known as cadherin 5 and CD144) is specifically responsible for endothelial AJ assembly and barrier architecture. In this review, VE-cadherin properties will be presented, along with the mechanisms involved in endothelial cell–cell junction remodeling.

Building VE-Cadherin Junctions and the Endothelial Barrier

The vascular wall compartmentalizes blood circulation from surrounding tissues, while allowing finely tuned exchanges of metabolites, fluids, and cells. Blood vessels are constructed with endothelial cells, pericytes, and smooth muscle cells, embedded within a specific basal membrane. From a molecular standpoint, the endothelial barrier is sealed by cell–cell adhesion molecules, among which VE-cadherin serves as a cornerstone.

VE-cadherin expression

VE-cadherin belongs to the super-family of classical cadherins, and as such, mediates homotypic calcium-dependent cell–cell interactions. VE-cadherin expression is tissue-specific and exclusive to endothelial cells, in a way that its promoter is repressed in other cell types and can be used to target the endothelial compartment in transgenic mice., Importantly, VE-cadherin gene knockout is lethal in mouse embryos that exhibit severe angiogenic defects, attributed to endothelial apoptosis and abnormal VEGF (vascular endothelial growth factor) signaling., Moreover, interfering with VE-cadherin in embryos and adult mice affects vascular integrity., Besides, silencing VE-cadherin expression and blocking its adhesive function in vitro provided evidence that this adhesion molecule is essential for AJ formation and endothelial barrier maintenance.- Accordingly, VE-cadherin emerges as the mastermind of endothelial cell–cell junctions, as it dictates the level of expression and/or the localization of other junctional molecules, including claudin-5 and N-cadherin.,,

VE-cadherin and its partners

Similarly to classical cadherins such as E- or N-cadherins, VE-cadherin recruits catenins through its cytosolic tail. These accessory molecules, mainly β-and p120-catenins, bridge cadherin multimers to the actin cytoskeleton via actin binding proteins, among which are α-catenin, vinculin, and eplin.- Interestingly, it has been recently observed that β-catenin dephosphorylation, together with VE-cadherin mobility, contribute to endothelial cell–cell junction stabilization. However, the role of β-catenin in the endothelial barrier remains complex, as this multifaceted protein is also an essential mediator of the Wnt signaling cascade, operating as a transcription factor in the nucleus. Thus, β-catenin may exert broader effects on gene expression and vascular plasticity, including barrier function.- Additionally, γ-catenin (also known as plakoglobin) can directly interact with VE-cadherin. Although β- and γ-catenins appear somehow interchangeable, only γ-catenin conveys VE-PTP adhesive function. On the other hand, p120-catenin, which interacts with VE-cadherin on its juxtamembrane domain, is a key regulator of VE-cadherin expression, trafficking, and stability at the plasma membrane.- Nonetheless, VE-cadherin rescue is not sufficient to maintain the endothelial barrier integrity in p120-depleted cells. This suggests a more complex role of p120-catenin in regulating cell–cell junction assembly in endothelial cells. In addition to catenins, a myriad of molecules are found in the vicinity of VE-cadherin, and could impact on the assembly and/or stability of VE-cadherin-mediated cellular interactions (Fig. 1). For instance, polarity complex proteins, including PAR3 and PAR6, accumulate at cell–cell junctions and interact with VE-cadherin. They were shown to modulate the overall architecture of endothelial cell–cell contacts, including AJs and TJs. Although their mode of action in endothelial AJs is not fully elucidated and probably differs from what is known in the context of epithelial cells, the polarity complex might engage additional signaling components required for the assembly of VE-cadherin junctions. This includes CCM1 (cerebral cavernous malformation protein 1), the GTPase Rap1, the atypical PKCζ (protein kinase C), and the G-protein exchange factor (GEF) Tiam (T-cell lymphoma invasion and metastasis). It is noteworthy that Rap1, together with its GEF, namely Epac, have extensively been demonstrated to favor the formation of VE-cadherin-based junctions. ,-

Figure 1. Assembly of VE-cadherin-mediated cell–cell contacts. Different classes of molecules interact with VE-cadherin (orange) and modulate its adhesive function: catenins (light green), actin binding proteins (red), phosphatases (purple), polarity complex (dark blue), signaling molecules and growth factor receptors (light blue), and microtubule (dark green). cat, catenin; cdc42, cell division control protein 42 homolog; CCM1, cerebral cavernous malformation protein 1; DEP1, density enhanced protein tyrosine phosphatase 1; EB3, end binding protein 3; FGFR, fibroblast growth factor receptor; PP2A, protein phosphatase 2A; PAR3/6, partition defect protein 3/6; PI3K, phosphoinositide 3 kinase; PKC, protein kinase C; PTP1B, protein tyrosine phosphatase 1B; Shp2, Src homology protein tyrosine phosphatase; Tiam, T-cell lymphoma invasion and metastasis; VE-cad, VE-cadherin; VEGFR2, vascular endothelial growth factor receptor 2; VE-PTP, vascular endothelial protein tyrosine phosphatase; vinc, vinculin.

Figure 1. Assembly of VE-cadherin-mediated cell–cell contacts. Different classes of molecules interact with VE-cadherin (orange) and modulate its adhesive function: catenins (light green), actin binding proteins (red), phosphatases (purple), polarity complex (dark blue), signaling molecules and growth factor receptors (light blue), and microtubule (dark green). cat, catenin; cdc42, cell division control protein 42 homolog; CCM1, cerebral cavernous malformation protein 1; DEP1, density enhanced protein tyrosine phosphatase 1; EB3, end binding protein 3; FGFR, fibroblast growth factor receptor; PP2A, protein phosphatase 2A; PAR3/6, partition defect protein 3/6; PI3K, phosphoinositide 3 kinase; PKC, protein kinase C; PTP1B, protein tyrosine phosphatase 1B; Shp2, Src homology protein tyrosine phosphatase; Tiam, T-cell lymphoma invasion and metastasis; VE-cad, VE-cadherin; VEGFR2, vascular endothelial growth factor receptor 2; VE-PTP, vascular endothelial protein tyrosine phosphatase; vinc, vinculin. Finally, serine/threonine and tyrosine phosphatases are part of the VE-cadherin interactome. Indeed, VE-PTP (vascular endothelial protein tyrosine phosphatase), shp2 (src homology protein tyrosine phosphatase2), PP2A (protein phosphatase 2A), DEP-1/CD148 (density enhanced protein tyrosine phosphatase 1), and PTP1B (protein tyrosine phosphatase 1B) were all found to directly stabilize VE-cadherin-based adhesion.,,- These enzymes are suspected to maintain VE-cadherin and associated catenins in a non-phosphorylated status, which in turn strengthens cell–cell adhesion.

VE-cadherin signaling

In addition to being associated with molecules that control its adhesive behavior, VE-cadherin coalesces signaling platforms at cell–cell contacts, involved in the endothelial biology, and in particular, barrier integrity. First, it has been early described that VE-cadherin function combines with VEGF-R2 (vegf receptor 2, also known as Flk1). They biochemically and functionally interact in quiescent endothelial cells, where VE-cadherin regulates VEGF-R2 antiapoptotic action.,, Interestingly, signaling pathways, which affect the endothelial plasticity in the course of angiogenesis, such as cell sprouting, migration, and permeability, frequently converge on the modulation of VE-cadherin/VEGF-R2 interaction.- In addition, VE-cadherin contributes to convey the proper activity of other receptors in endothelial cells, such as angiopoietin 1 receptor Tie2, TGFβ-R2 (transforming growth factor receptor), and FGF (fibroblast growth factor) signaling.,- Besides membrane receptors, VE-cadherin triggers the activation of intracellular molecules, such as small GTPases from the Ras superfamily, which can loop on cell–cell adhesion. Notably, VE-cadherin induces Rac activation through Tiam.- In addition, VE-cadherin is able to increase PI3K (phosphoinositide 3 kinase) catalytic activity, which can signal through the nucleus via FoxO1 and β-catenin transcription factors, to maintain endothelial features., Finally, it has been elegantly demonstrated that VE-cadherin could stabilize cell–cell contacts and organize the endothelial barrier through an original outside-in signaling mechanism, involving calcium signaling and microtubule dynamics. There are a growing number of molecules detected at endothelial AJs that can adjust VE-cadherin expression, cell surface availability, phosphorylation status, turnover, and signaling. Targeting each of these properties could be employed to tune endothelial permeability and vascular leakage.

Breaking Down VE-Cadherin Junctions and the Endothelial Barrier

VE-cadherin is instrumental for vascular integrity, and therefore, is the target of a plethora of signaling events, which can provoke endothelial barrier disruption and vascular permeability increase (Fig. 2).

Figure 2. Disassembly of VE-cadherin-mediated cell–cell contacts. Four main routes modulate VE-cadherin disassembly and vascular permeability: (1) phosphorylation within VE-cadherin (VE-cad) C-tail and associated catenins on Y and S. At least, PAK (p21-activated kinase), Src, and FAK (focal adhesion kinase) were shown to catalyze VE-cadherin phosphorylation. This post-translational modification can ultimately lead to VE-cadherin/catenin dissociation; (2) internalization into clathrin-coated vesicles (CCV), which depends on p120-catenin (cat) and VE-cad phosphorylation; (3) mechanical forces and tension exerted on cell adhesion, notably through the actin cytoskeleton and Rho GTPases; and (4) expression regulated either at the transcriptional level through transcription factors (TF) and miRNA (miR), or at the protein level through extracellular shedding or intracellular cleavage, ubiquitin-, and lysosomal-driven degradation. P is for phosphorylation.

Figure 2. Disassembly of VE-cadherin-mediated cell–cell contacts. Four main routes modulate VE-cadherin disassembly and vascular permeability: (1) phosphorylation within VE-cadherin (VE-cad) C-tail and associated catenins on Y and S. At least, PAK (p21-activated kinase), Src, and FAK (focal adhesion kinase) were shown to catalyze VE-cadherin phosphorylation. This post-translational modification can ultimately lead to VE-cadherin/catenin dissociation; (2) internalization into clathrin-coated vesicles (CCV), which depends on p120-catenin (cat) and VE-cad phosphorylation; (3) mechanical forces and tension exerted on cell adhesion, notably through the actin cytoskeleton and Rho GTPases; and (4) expression regulated either at the transcriptional level through transcription factors (TF) and miRNA (miR), or at the protein level through extracellular shedding or intracellular cleavage, ubiquitin-, and lysosomal-driven degradation. P is for phosphorylation.

VE-cadherin phosphorylation

The cytosolic tail of VE-cadherin harbors nine putative phospho-tyrosine sites, among which Y645, Y658, Y685, Y731, and Y733 that could be implicated in barrier integrity.- In addition, VE-cadherin serine phosphorylation on the S665 residue has been shown to modulate AJ assembly., Indeed, many vascular-promoting agents, such as VEGF and histamine, were extensively documented to increase the phosphorylation of VE-cadherin and of associated catenins; resulting in the loosening of VE-cadherin/catenin binding. Conversely, the artificial stabilization of VE-cadherin/catenin complexes hampers vascular permeability and leukocyte extravasation. Several kinases were proposed to catalyze VE-cadherin phosphorylation, while the exact molecular mechanisms linking phosphorylation to vascular leakage remains to be elucidated. To this regard, the non-receptor tyrosine kinase Src was demonstrated to contribute to the phosphorylation of VE-cadherin and catenins, and to AJ disassembly.,,,- However, Src-directed VE-cadherin phosphorylation appears insufficient to drive endothelial barrier opening, even when its activity was upregulated through the expression of a Src dominant active mutant or a Csk (C-terminal Src kinase) dominant negative form. Besides Src, FAK (focal adhesion kinase) emerges as a prominent mediator of VE-cadherin-mediated AJ disorganization and permeability elevation., PAK (p21-activated kinase) could also phosphorylate VE-cadherin on serine, causing its internalization and cell–cell junction weakening. An alternate mechanism for VE-cadherin/catenin dissociation and enhanced permeability relies on caveolin phosphorylation, which could, in its phosphorylated form, trap catenins away from VE-cadherin.

VE-cadherin and mechanical forces

It is now widely accepted that mechanical tension exerted on endothelial cells, such as shear stress, can be sensed and integrated through VE-cadherin and VEGF-R2 complexes, although an additional adhesion molecule, namely PECAM (also referred to as CD31), is essential to transduce tensile forces.- Multiple signaling pathways have been further demonstrated to convey and adapt the endothelial cellular responses to environmental forces. The most studied one corresponds to the modulation of the acto-myosin contractility apparatus via the activation of small GTPases, including RhoA, Rac, and cdc42, and myosin light chain (MLC) phosphorylation. However, the individual contribution of RhoA, Rac, and cdc42 to the endothelial barrier function might depend on cellular context and extracellular cues. For instance, thrombin primarily operates through RhoA that induces stress fiber formation and endothelial barrier permeability increase, while histamine mainly uses cdc42.- Likewise, Rac mediates VEGF-induced permeability, while it is essential for cell–cell contact formation upon VE-cadherin transactivation., Conversely, VE-cadherin can also impact cellular tension through direct signaling to GTPases, as mentioned earlier.-,

VE-cadherin internalization

Availability of VE-cadherin at the plasma membrane is instrumental in regulating cell–cell adhesion and endothelial barrier function.,, Indeed, it is recognized that VE-cadherin is a highly dynamic adhesion molecule, whose endosomal trafficking through clathrin-coated vesicles is tightly controlled.,, As cadherin internalization is associated with cell–cell junction loosening, this mechanism could contribute to endothelial behavior, such as cell migration and permeability.,,- How VE-cadherin trafficking is dynamically modulated in endothelial cells has been the focus of intense investigation. In particular, it has been shown that p120-catenin could inhibit constitutive and induced VE-cadherin endocytosis., A cluster of three amino acids has been further identified within the core p120-binding region to the VE-cadherin cytosolic tail. This sequence is responsible for VE-cadherin uptake. In addition, VE-cadherin phosphorylation on serine and tyrosine residues has been shown to provoke its internalization both in vitro and in vivo, leading to increase in vascular permeability.,,,,,,- Again, several signaling pathways have been shown to impact the entry of VE-cadherin in clathrin-coated pits. For instance, PI3K signaling is involved in VE-cadherin internalization and loss of vascular barrier, although the exact molecular mechanisms are not fully elucidated.,- Depending on the signal input, such as VEGF, chemokines, and inflammation, different PI3K isoforms can be engaged in VE-cadherin trafficking. For instance, class I PI3Kα transduces TNFα (tumor necrosis factor α) signaling to VE-cadherin destabilization, while PI3Kγ conveys chemokine’s one.- On the other hand, class II PI3K-C2α deletion specifically impairs vascular sprouting and maturation in mice, most likely in response to VEGF. Additionally, Src kinase also triggers VE-cadherin internalization, directly through its phosphorylation or of its associated molecules, or through the activation of other kinases, such as PAK.,,, Conversely, anti-permeability agents could operate through the blockade of VE-cadherin internalization.,,

VE-cadherin availability

During physiological and pathological blood vessel formation and in response to vascular permeability-promoting agents, the endothelial barrier function could be directly altered through the level of expression of VE-cadherin. This could be achieved by playing on either transcription of VE-cadherin mRNA or on the protein turnover. As mentioned above, VE-cadherin promoter is repressed in non-endothelial cells, and can be activated in response to angiogenic signals, such as FGF. Interestingly, several transcription factors have been identified for their positive action on VE-cadherin expression, notably during developmental angiogenesis and inflammation. For instance, the Kruppel-like factor 4 (KLF4) binds VE-cadherin promoter and enhances its transcription, most likely downstream Wnt3a/β-catenin signaling. Interestingly, KLF4 depletion leads to VE-cadherin reduction, loss of AJ and of barrier integrity. This might ultimately aggravated lung vascular leakage in bacteria lipopolysaccharide (LPS) challenge. Likewise, Wnt3a/β-catenin signaling controls claudin-3 expression and barrier maturation, albeit β-catenin cooperates with FoxO1 to repress claudin-5 expression., Thus, the respective action of Wnt signaling and β-catenin in VE-cadherin transcription remains far from being understood. Keeping with this, the catenin p120 could also play an essential role on VE-cadherin transcription, as its depletion in mice leads to VE-cadherin downregulation, microvasculature disorganization, and loss of vascular integrity. Additional nuclear factors were discovered to control the endothelial barrier through their binding to the VE-cadherin promoter, including the ETS-related gene Erg, the hypoxia-inducing factor HIF2α, the basic helix-loop-helix TAL-1/SCL, the scaffold protein β-arrestin, the Sex-determining region Y (SRY)-related HMG box transcription factor Sox7, and the serum response element SRF., - Additionally, several miRNA, which have emerged as endogenous non-coding RNA molecules able to downregulate gene expression, have been found implicated in the regulation of VE-cadherin expression. For instance, miR27a can control VE-cadherin expression, angiogenesis, and vascular permeability. Interestingly, blocking specifically miR27a-dependent VE-cadherin repression precludes edema formation in vivo. Likewise, miR101, miR125b, and miR142a can transcriptionally hamper on VE-cadherin expression, and impact on angiogenesis and permeability in vivo.- Conversely, the combination of miR99b and miR181a/b enhances endothelial differentiation, and notably, the expression of VE-cadherin in human embryonic stem cells. Finally, VE-cadherin protein expression can be regulated at the post-translational level through ubiquitination-driven processing, lysosomal degradation, and proteolytic cleavage by a desintegrin and metalloprotease ADAM10 and m-calpain.,- This latter can directly cleave VE-cadherin, leading to AJ disassembly and increased vascular leakage, associated with atherosclerosis lesions. However, the molecular mechanisms that specifically control VE-cadherin turnover remain elusive. For instance, neither the ubiquitin ligases, nor the lysine residues involved in VE-cadherin ubiquitination have been identified so far. Our knowledge on the molecular mechanisms involved in vascular permeability elevation has been improved. To this regard, any deregulation of this central function takes part in the initiation and progression of many pathological conditions and human diseases., It is now accepted that VE-cadherin-mediated cell–cell adhesion organizes the endothelial junctions and maintains the barrier function. Now that many partners of VE-cadherin involved in assembly/disassembly of endothelial junctions have been identified, efforts have to be done to uncover the mechanistic differences that may exist between physiological and pathological permeability increase. In addition, restoring endothelial cell–cell junctions could normalize vascular barrier function and therefore be of high interest in medicine.
  105 in total

1.  Epac1 regulates integrity of endothelial cell junctions through VE-cadherin.

Authors:  Matthijs R H Kooistra; Monica Corada; Elisabetta Dejana; Johannes L Bos
Journal:  FEBS Lett       Date:  2005-09-12       Impact factor: 4.124

2.  Endocytosis of cadherin from intracellular junctions is the driving force for cadherin adhesive dimer disassembly.

Authors:  Regina B Troyanovsky; Eugene P Sokolov; Sergey M Troyanovsky
Journal:  Mol Biol Cell       Date:  2006-06-07       Impact factor: 4.138

Review 3.  Breaking the VE-cadherin bonds.

Authors:  Julie Gavard
Journal:  FEBS Lett       Date:  2008-12-04       Impact factor: 4.124

4.  VE-cadherin trans-interactions modulate Rac activation and enhancement of lung endothelial barrier by iloprost.

Authors:  Anna A Birukova; Yufeng Tian; Oleksii Dubrovskyi; Noureddine Zebda; Nicolene Sarich; Xinyong Tian; Yingxiao Wang; Konstantin G Birukov
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

5.  Caveolin-1 opens endothelial cell junctions by targeting catenins.

Authors:  Romy Kronstein; Jochen Seebach; Sylvia Grossklaus; Carsten Minten; Britta Engelhardt; Marek Drab; Stefan Liebner; Yvan Arsenijevic; Abdallah Abu Taha; Tatiana Afanasieva; Hans-Joachim Schnittler
Journal:  Cardiovasc Res       Date:  2011-09-29       Impact factor: 10.787

6.  ETS-related gene (ERG) controls endothelial cell permeability via transcriptional regulation of the claudin 5 (CLDN5) gene.

Authors:  Lei Yuan; Alexandra Le Bras; Anastasia Sacharidou; Kiyoshi Itagaki; Yumei Zhan; Maiko Kondo; Christopher V Carman; George E Davis; William C Aird; Peter Oettgen
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

7.  TGF-beta1 induces rearrangement of FLK-1-VE-cadherin-beta-catenin complex at the adherens junction through VEGF-mediated signaling.

Authors:  Brandoch D Cook; Giovanni Ferrari; Giuseppe Pintucci; Paolo Mignatti
Journal:  J Cell Biochem       Date:  2008-12-15       Impact factor: 4.429

8.  Phosphorylation of vascular endothelial cadherin controls lymphocyte emigration.

Authors:  Patric Turowski; Roberta Martinelli; Rebecca Crawford; David Wateridge; Anna-Pia Papageorgiou; Maria Grazia Lampugnani; Alexander C Gamp; Dietmar Vestweber; Peter Adamson; Elisabetta Dejana; John Greenwood
Journal:  J Cell Sci       Date:  2008-01-01       Impact factor: 5.285

9.  Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis.

Authors:  Sara Weis; Jianhua Cui; Leo Barnes; David Cheresh
Journal:  J Cell Biol       Date:  2004-10-25       Impact factor: 10.539

10.  VE-cadherin regulates endothelial actin activating Rac and increasing membrane association of Tiam.

Authors:  Maria Grazia Lampugnani; Adriana Zanetti; Ferruccio Breviario; Giovanna Balconi; Fabrizio Orsenigo; Monica Corada; Raffaella Spagnuolo; Martha Betson; Vania Braga; Elisabetta Dejana
Journal:  Mol Biol Cell       Date:  2002-04       Impact factor: 4.138

View more
  69 in total

1.  Transient receptor potential channel 1 maintains adherens junction plasticity by suppressing sphingosine kinase 1 expression to induce endothelial hyperpermeability.

Authors:  Mohammad Tauseef; Mohammad Farazuddin; Sukriti Sukriti; Charu Rajput; James Otto Meyer; Suresh Kumar Ramasamy; Dolly Mehta
Journal:  FASEB J       Date:  2015-08-27       Impact factor: 5.191

2.  Phospholipase D2 restores endothelial barrier function by promoting PTPN14-mediated VE-cadherin dephosphorylation.

Authors:  Panfeng Fu; Ramaswamy Ramchandran; Mark Shaaya; Longshuang Huang; David L Ebenezer; Ying Jiang; Yulia Komarova; Stephen M Vogel; Asrar B Malik; Richard D Minshall; Guangwei Du; Nicholas K Tonks; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2020-04-23       Impact factor: 5.157

3.  Sex differences influencing micro- and macrovascular endothelial phenotype in vitro.

Authors:  Virginia H Huxley; Scott S Kemp; Christine Schramm; Steve Sieveking; Susan Bingaman; Yang Yu; Isabella Zaniletti; Kevin Stockard; Jianjie Wang
Journal:  J Physiol       Date:  2018-07-15       Impact factor: 5.182

4.  Oxygen-Glucose Deprivation/Reoxygenation Induces Human Brain Microvascular Endothelial Cell Hyperpermeability Via VE-Cadherin Internalization: Roles of RhoA/ROCK2.

Authors:  Jie Chen; Li Sun; Gui-Bing Ding; Liang Chen; Lei Jiang; Jun Wang; Jin Wu
Journal:  J Mol Neurosci       Date:  2019-06-11       Impact factor: 3.444

5.  Bone Morphogenetic Protein-Modulator BMPER Regulates Endothelial Barrier Function.

Authors:  Thomas Helbing; Gwendoline Wiltgen; Alexandra Hornstein; Elena Z Brauers; Linus Arnold; Adrian Bauer; Jennifer S Esser; Philipp Diehl; Sebastian Grundmann; Katrin Fink; Cam Patterson; Christoph Bode; Martin Moser
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

6.  Human brain microvascular endothelial cell pairs model tissue-level blood-brain barrier function.

Authors:  Blakely B O'Connor; Thomas Grevesse; John F Zimmerman; Herdeline Ann M Ardoña; Jorge A Jimenez; Dimitrios Bitounis; Philip Demokritou; Kevin Kit Parker
Journal:  Integr Biol (Camb)       Date:  2020-04-14       Impact factor: 2.192

7.  High-Throughput Tumor-on-a-Chip Platform to Study Tumor-Stroma Interactions and Drug Pharmacokinetics.

Authors:  Chun-Wei Chi; Yeh-Hsing Lao; A H Rezwanuddin Ahmed; Elizabeth C Benoy; Chenghai Li; Zeynep Dereli-Korkut; Bingmei M Fu; Kam W Leong; Sihong Wang
Journal:  Adv Healthc Mater       Date:  2020-09-23       Impact factor: 9.933

8.  The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions.

Authors:  Amnah Yamani; David Wu; Lisa Waggoner; Taeko Noah; Anthony J Koleske; Fred Finkelman; Simon P Hogan
Journal:  J Allergy Clin Immunol       Date:  2017-11-17       Impact factor: 10.793

9.  Activation of Vascular Endothelial Growth Factor (VEGF) Receptor 2 Mediates Endothelial Permeability Caused by Cyclic Stretch.

Authors:  Yufeng Tian; Grzegorz Gawlak; James J O'Donnell; Anna A Birukova; Konstantin G Birukov
Journal:  J Biol Chem       Date:  2016-02-16       Impact factor: 5.157

10.  Spatial Memory Disturbance Following Transient Brain Ischemia is Associated with Vascular Remodeling in Hippocampus.

Authors:  Ery Hermawati; Nur Arfian; Ginus Partadiredja
Journal:  Kobe J Med Sci       Date:  2018-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.